Home › Compare › YORW vs GILD

YORW vs GILD: Dividend Comparison 2026

YORW yields 4.00% · GILD yields 2.34%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GILD wins by $1.1K in total portfolio value· pulled ahead in Year 9
10 years
YORW
YORW
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full YORW calculator →
GILD
GILD
● Live price
2.34%
Share price
$136.34
Annual div
$3.19
5Y div CAGR
17.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.1K
Annual income
$1,614.90
Full GILD calculator →

Portfolio growth — YORW vs GILD

📍 GILD pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYORWGILD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YORW + GILD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
YORW pays
GILD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YORW
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
GILD
Annual income on $10K today (after 15% tax)
$198.88/yr
After 10yr DRIP, annual income (after tax)
$1,372.67/yr
At 15% tax rate, GILD beats the other by $608.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YORW + GILD for your $10,000?

YORW: 50%GILD: 50%
100% GILD50/50100% YORW
Portfolio after 10yr
$28.6K
Annual income
$1,257.05/yr
Blended yield
4.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GILD right now

YORW
Analyst Ratings
3
Hold
1
Sell
Consensus: Hold
Altman Z
0.9
Piotroski
4/9
GILD
Analyst Ratings
37
Buy
20
Hold
1
Sell
Consensus: Buy
Price Target
$158.71
+16.4% upside vs current
Range: $105.00 — $180.00
Altman Z
4.1
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YORW buys
0
GILD buys
0
No recent congressional trades found for YORW or GILD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYORWGILD
Forward yield4.00% ✓2.34%
Annual dividend / share$2.00$3.19 ✓
Payout ratio50%50%
1-year div growth5% ✓0%
5-year div CAGR5%17.3% ✓
Portfolio after 10y$28.0K$29.1K ✓
Annual income after 10y$899.19$1,614.90 ✓
Total dividends collected$6.4K$7.6K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: YORW vs GILD ($10,000, DRIP)

YearYORW PortfolioYORW Income/yrGILD PortfolioGILD Income/yrGap
1$11,120$420.00$10,974$274.45+$146.00 → YORW
2$12,357$458.31$12,073$330.19+$284.00 → YORW
3$13,721$499.76$13,316$398.20+$405.00 → YORW
4$15,227$544.58$14,730$481.49+$497.00 → YORW
5$16,885$593.02$16,345$583.87+$540.00 → YORW
6$18,713$645.34$18,199$710.26+$514.00 → YORW
7$20,724$701.81$20,340$866.96+$384.00 → YORW
8$22,938$762.73$22,826$1,062.22+$112.00 → YORW
9← crossover$25,372$828.41$25,731$1,306.80$359.00 → GILD
10$28,047$899.19$29,147$1,614.90$1.1K → GILD

YORW vs GILD: Complete Analysis 2026

YORW — Stock

YORW is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in YORW shares.

Full YORW Calculator →

GILD — Healthcare

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Full GILD Calculator →
📬

Get this YORW vs GILD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YORW vs SCHDYORW vs JEPIYORW vs OYORW vs KOYORW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.